Agios Taps Wall Street Off Early Data, Aims For $75M

Agios taps Wall Street off early data, aims for $75M.

Apr 10, 2014 at 9:53AM

Agios Pharmaceuticals (NASDAQ:AGIO) gave investors its first glimpse of encouraging, but early human clinical data a few days ago, and saw its shares soar as a result. Now, it's looking to cash in.

Cambridge, MA-based Agios wants to raise up to $75 million through a public stock offering, according to a regulatory filing. Agios had about $194 million in cash at the end of 2013, and is eyeing the extra dollars from the public markets to move its prospective cancer metabolism drugs—AG-221, AG-120, and AG-348—through their respective early stage studies.

The offering comes during a week where Agios' shares have climbed more than 36 percent. Its shares closed Wednesday at $48.42 apiece, the company's highest closing price since debuting on the Nasdaq in July.

Investors have piled into the stock after Agios produced an interim look at its first clinical trial for AG-221, a potential treatment for cancers with the IDH2 mutation. Agios only has data from seven patients with acute myeloid leukemia so far, but six of them responded to AG-221, and three of them had no trace of cancer in their blood after 28 days of treatment.  This is despite the fact that those patients only received the lowest two of four planned dosages of Agios's drug.

There's still much data to accrue, and it's unclear at this point how durable each of these responses are—or if Agios will even get the same type of responses out of the next batch of patients. But the results were a promising sign for Agios's approach of going after cellular metabolism targets. The data, for instance, had analysts talking up streamlined regulatory approval paths for AG-221.

"While patient numbers are small, there appears to be more than enough activity to support a potential accelerated approval strategy based on a single arm Phase 2 trial assuming even a 2-3 month duration of response," wrote Leerink Partners analyst Howard Liang in a note to investors.

Summit, NJ-based Celgene holds worldwide rights to AG-221 as part of the partnership it struck with Agios in 2009. About 10 to 15 percent of patients with AML, a fast-moving type of blood cancer, have the IDH2 mutation. AML patients are typically treated with chemotherapy, and often wind up needing bone marrow transplants.

You can read my wrap on the AG-221 study results here.

The 9-minute dividend strategy you need to know
One of the dirty secrets that few finance professionals will openly admit is the fact that dividend stocks as a group handily outperform their non-dividend paying brethren. The reasons for this are too numerous to list here, but you can rest assured that it's true. However, knowing this is only half the battle. The other half is identifying which dividend stocks in particular are the best. With this in mind, our top income analyst put together a report outlining a simple 9-minutes-a-year dividend strategy that should be in every income investor's toolkit. To learn more about this "tax-skipping" dividend trick, all you have to do is click here now.

This article originally appeared on Xconomy, along with:

Ben Fidler has no position in any stocks mentioned. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers